- Home
- DTIL vs IVVD Comparison
DTIL vs IVVD Comparison
Compare DTIL & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- IVVD
- Stock Information
- Founded
- DTIL 2006
- IVVD 2020
- Country
- DTIL United States
- IVVD United States
- Employees
- DTIL N/A
- IVVD N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- IVVD Health Care
- Exchange
- DTIL Nasdaq
- IVVD Nasdaq
- Market Cap
- DTIL 55.3M
- IVVD 63.4M
- IPO Year
- DTIL 2019
- IVVD 2021
- Fundamental
- Price
- DTIL $4.96
- IVVD $0.52
- Analyst Decision
- DTIL Strong Buy
- IVVD Strong Buy
- Analyst Count
- DTIL 2
- IVVD 3
- Target Price
- DTIL $47.00
- IVVD $3.85
- AVG Volume (30 Days)
- DTIL 84.3K
- IVVD 1.2M
- Earning Date
- DTIL 08-07-2025
- IVVD 08-14-2025
- Dividend Yield
- DTIL N/A
- IVVD N/A
- EPS Growth
- DTIL N/A
- IVVD N/A
- EPS
- DTIL N/A
- IVVD N/A
- Revenue
- DTIL $1,261,000.00
- IVVD $46,210,000.00
- Revenue This Year
- DTIL N/A
- IVVD $345.16
- Revenue Next Year
- DTIL $135.19
- IVVD $161.08
- P/E Ratio
- DTIL N/A
- IVVD N/A
- Revenue Growth
- DTIL N/A
- IVVD 1941.08
- 52 Week Low
- DTIL $3.61
- IVVD $0.35
- 52 Week High
- DTIL $11.09
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- DTIL 56.59
- IVVD 32.49
- Support Level
- DTIL $4.55
- IVVD $0.48
- Resistance Level
- DTIL $4.99
- IVVD $0.65
- Average True Range (ATR)
- DTIL 0.32
- IVVD 0.06
- MACD
- DTIL 0.02
- IVVD -0.03
- Stochastic Oscillator
- DTIL 81.11
- IVVD 11.35
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.